Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00023621 · ClinicalTrials.gov registry record · Phase 2
Celecoxib in Preventing Basal Cell Carcinoma in Patients With Basal Cell Nevus Syndrome
A Phase 2 study of Non-melanomatous Skin Cancer, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 2
- Study locations
NCT00023621 is a Phase 2 study of Non-melanomatous Skin Cancer that has completed, run by University of California, San Francisco. The registered enrollment target is 60 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT00023621, a Phase 2 study of Non-melanomatous Skin Cancer, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 2
- Study locations
Study Summary
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. The use of celecoxib may be an effective way to prevent the development of basal cell carcinoma. PURPOSE: Randomized phase II trial to determine the effectiveness of celecoxib in preventing basal cell carcinoma in patients who have basal cell nevus syndrome.
Conditions Studied
Interventions
- DRUG celecoxib
Study Locations (2)
California
- UCSF Comprehensive Cancer Center - San Francisco
New York
- Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2001-02 |
| Est. Completion | 2007-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00023621
The ClinicalTrials.gov registry entry for NCT00023621 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-melanomatous Skin Cancer appearing as the primary indexed condition, and to 1 intervention - of which celecoxib is the first listed.
NCT00023621 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, New York.
Frequently Asked Questions
What is clinical trial NCT00023621 about?
NCT00023621 is a clinical study titled "Celecoxib in Preventing Basal Cell Carcinoma in Patients With Basal Cell Nevus Syndrome". RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. The use of celecoxib may be an effective way to prevent the development of basal cell carcinoma. PURPOSE: Randomized phase II trial to determine the effectiveness of celecoxib in preventing b...
What is the current status of trial NCT00023621?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2001-02. Estimated completion is 2007-07.
What conditions does trial NCT00023621 study?
This clinical trial studies the following conditions: Non-melanomatous Skin Cancer.
What interventions are being tested in trial NCT00023621?
The interventions under investigation include: celecoxib (DRUG).
Who is sponsoring clinical trial NCT00023621?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00023621 being conducted?
This trial has 2 study locations across California, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-melanomatous Skin Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.